tradingkey.logo

Rezolute Announces Completion Of Enrollment In The Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism

ReutersMay 28, 2025 1:28 PM

- Rezolute Inc RZLT.O:

  • REZOLUTE ANNOUNCES COMPLETION OF ENROLLMENT IN THE PHASE 3 SUNRIZE STUDY OF ERSODETUG IN PATIENTS WITH CONGENITAL HYPERINSULINISM

  • REZOLUTE INC - TOPLINE DATA ANTICIPATED IN DECEMBER 2025

  • REZOLUTE INC - ANTICIPATES BLA SUBMISSION FOR ERSODETUG IN 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI